Recognising World Cancer Research Day – Icon Group Launches Theranostics Research Program

Goals of the Theranostics Research Program

As part of our continued investment in theranostics and molecular oncology we’re proud to begin the delivery of a comprehensive theranostics research program. This program aims to:

• Personalise treatment: discover and contribute to new and emerging therapies tailored to individual patients based on their unique genetic and molecular profiles.
• Improved outcomes: enhance the effectiveness of cancer treatments, leading to better patient outcomes and quality of life for more people.
• Drive the future of cancer research: foster cutting-edge theranostics research and collaboration with leading clinicians and institutions through innovation, data-driven approaches and patient-centred solutions.
• Increase accessibility: ensure that advancements in theranostics are available to more patients and communities.

Future Healthcare

Icon’s Group Director of Molecular Oncology, Julie Crouch says participating in research is an exciting step forward in our theranostics capabilities.

“Molecular oncology is seeing significant advances, and we’ve had a real positive start to our theranostics program at North Lakes which is giving people greater access to this treatment,” said Julie.

“We’re now looking forward to contributing to clinical trials that have the aim of transforming this cutting-edge treatment and providing new lines of therapies to not only people in Queensland, but nationally and into Singapore,” said Julie.

Excellence in Research

The theranostics research program is led by Icon Group Executive Manager, Sophie Mepham, alongside Julie Crouch, Clinical Director for Molecular Imaging and Nuclear Oncology (Asia Pacific), Dr Nat Lenzo, and Nuclear Medicine Physician, A/Prof David Macfarlane.

The program is scheduled to open its first trials at Icon Cancer Centre North Lakes and Icon Cancer Centre Kurralta Park in Adelaide later this year, locally led by Clinical Research Coordinator Team Lead, Jesse Peet (North Lakes) and State Research Coordinator Manager, Sue Yeend (Adelaide).

“At Icon, we’re fortunate to have highly experienced and internationally recognised molecular oncology specialists and a centralised research team pushing forward advancements in precision medicine,” said Julie.

“Our global integrated network will allow for the safe and efficient rollout of theranostics research which we intend to introduce to Singapore next year and into the United Kingdom in the future.” Learn more about research at Icon.

Access our Annual Research Report.

For more information about our theranostics visit Icon Cancer Centre Australia.